A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Recombinant Human Parathyroid Hormone, PTH (Forteo).
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2009
At a glance
- Drugs Teriparatide (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Pfizer
- 20 Mar 2009 Actual end date changed from Mar 2008 to Apr 2008 as reported by ClinicalTrials.gov.
- 26 Jun 2008 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
- 26 Jun 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.